Epidermal growth factor receptor tyrosine kinase inhibitors for non‐small cell lung cancer harboring uncommon EGFR mutations: Real‐world data from Taiwan
JWC Chang, CY Huang, YF Fang, CF Chang… - Thoracic …, 2023 - Wiley Online Library
Background Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) are the
standard treatment for patients with non‐small cell lung cancer (NSCLC) harboring EGFR …
standard treatment for patients with non‐small cell lung cancer (NSCLC) harboring EGFR …
Sequential treatment in advanced non–small cell lung cancer harboring EGFR mutations
PC Hsu, JWC Chang, CF Chang… - Therapeutic …, 2022 - journals.sagepub.com
Background: Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are
standard treatments for advanced EGFR-mutated non–small cell lung cancer (NSCLC) …
standard treatments for advanced EGFR-mutated non–small cell lung cancer (NSCLC) …
Impact of T790M mutation status on Later-Line osimertinib treatment in non-small cell lung cancer patients
YJ Tang, JWC Chang, CF Chang, CY Huang, CT Yang… - Cancers, 2022 - mdpi.com
Simple Summary Osimertinib is a third-generation epidermal growth factor receptor tyrosine
kinase inhibitor (EGFR-TKI) designed to overcome acquired T790M resistance mutations in …
kinase inhibitor (EGFR-TKI) designed to overcome acquired T790M resistance mutations in …
[HTML][HTML] Effectiveness and safety of afatinib, gefitinib, and erlotinib for treatment-naïve elderly patients with epidermal growth factor receptor-mutated advanced non …
LJ Hung, PC Hsu, CT Yang, CHS Kuo… - Aging (Albany …, 2024 - ncbi.nlm.nih.gov
Background: In real-world practice, most patients with lung cancer are diagnosed when they
are aged≥ 65 years. However, clinical trials tend to lack data for the elderly population …
are aged≥ 65 years. However, clinical trials tend to lack data for the elderly population …
Local Consolidative Therapy May Have Prominent Clinical Efficacy in Patients with EGFR-Mutant Advanced Lung Adenocarcinoma Treated with First-Line Afatinib
Simple Summary Afatinib is an irreversible epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitor (TKI) used to treat patients with advanced EGFR-mutant lung cancer. In this …
kinase inhibitor (TKI) used to treat patients with advanced EGFR-mutant lung cancer. In this …
Novel bioactive 2‐phenyl‐4‐aminopyrimidine derivatives as EGFRDel19/T790M/C797S inhibitors for the treatment of non‐small cell lung cancer
S Xu, Z Zhou, J He, J Guo, X Huang, Y An… - Archiv der …, 2024 - Wiley Online Library
Overexpression of the epidermal growth factor receptor (EGFR) has been implicated in the
development of non‐small‐cell lung cancer (NSCLC). Thus, EGFR is an effective drug target …
development of non‐small‐cell lung cancer (NSCLC). Thus, EGFR is an effective drug target …
[HTML][HTML] Does dose reduction of afatinib affect treatment outcomes of patients with EGFR-mutant metastatic non-small cell lung cancer in real-world clinical practice?
Background Afatinib can be started at a dose lower than the recommended starting dose of
40 mg/day for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small …
40 mg/day for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small …
[HTML][HTML] Real-world first-line afatinib for advanced EGFR mutation-positive non-small cell lung cancer in Korea: updated survival data
J Choi, CM Choi, YS Chang, KY Lee… - Translational Lung …, 2023 - ncbi.nlm.nih.gov
Background Data from clinical trials and real-world studies show that afatinib is effective in
treating non-small cell lung cancer (NSCLC) harboring activating mutations in the epidermal …
treating non-small cell lung cancer (NSCLC) harboring activating mutations in the epidermal …
Comprehensive assessment of pretreatment sarcopenia impacts on patients with EGFR‐mutated NSCLC treated with afatinib
CT Wu, PC Hsu, JWC Chang, CF Chang… - Thoracic …, 2023 - Wiley Online Library
Background This study aimed to comprehensively evaluate the efficacy and toxicity of
afatinib in patients with sarcopenia, an important prognostic factor for treatment efficacy and …
afatinib in patients with sarcopenia, an important prognostic factor for treatment efficacy and …
小分子靶向抗肿瘤药物耐药机制与应对策略
廖敏， 强晓妍， 盛泽娟， 彭鹏 - 药学进展, 2023 - pps.cpu.edu.cn
癌症是危害人类健康的重要因素, 并已经成为全球第二大致死病因. 随着小分子靶向抗癌药物的
出现与广泛应用, 癌症的治愈率与患者的生存期均显著提高. 但肿瘤耐药问题随之而来 …
出现与广泛应用, 癌症的治愈率与患者的生存期均显著提高. 但肿瘤耐药问题随之而来 …